Health

PreclinicalBiologic

WWageningen University

Health is one of 41 biologic programs targeting Myocardial Infarction. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myocardial InfarctionActive, not recruiting

Myocardial InfarctionPreclinical

Active, not recruiting

Competition

Competitive Landscape

232 competitors in Myocardial Infarction

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Phase 3

2 2

Ikorel

Merck & Co.

Phase 3

2 3

Medrol

Pfizer

Phase 3

2 4

Lovenox

Sanofi

Phase 3

1 5

Eliquis

Bristol-Myers Squibb

Phase 3

1 6

Aranesp

Reopro

4 8

Zetia

OOrganon and Co

Phase 3

3 9

Jardiance

Boehringer Ingelheim

Phase 3

2 10

Tekturna

Tibotec Pharmaceuticals, Ireland

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2040

Active, not recruiting

Myocardial Infarction

NCT03192410

Clinical

Trials by Indication[1]

Myocardial Infarction1 trial

Prospective Cohort Study of 4,837 Post-myocardial Infarction Patients (Alpha Omega Cohort)

Active, not recruiting·WWageningen University··NCT03192410·4,837 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Health. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Health compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Health. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Wageningen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: WWageningen University

Health

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2040

Trials by Indication[1]

Myocardial Infarction1 trial

References

Drug Info

Quick Facts

Related News